Download PDF
Horm Metab Res 2015; 47(09): 652-655
DOI: 10.1055/s-0035-1547234
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas

B. A. Doğan
1   Endocrinology and Metabolism Disease, Darıca Farabi State Hospital, Kocaeli, Turkey
,
M. M. Tuna
2   Endocrinology and Metabolism Disease, Dicle University, Diyarbakır, Turkey
,
A. Arduç
3   Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes, National Institutes of Health, Bethesda, Maryland, USA
,
M. N. Başaran
4   Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
K. Küçükler
5   Endocrinology and Metabolism Disease, Hitit University, Çorum, Turkey
,
I. Dağdelen
4   Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
D. Berker
4   Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
S. Güler
4   Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
5   Endocrinology and Metabolism Disease, Hitit University, Çorum, Turkey
› Author Affiliations
Further Information

Publication History

received 25 September 2014

accepted 03 February 2015

Publication Date:
06 March 2015 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.

Key words

androgens - atherosclerotic risk markers - clinically nonfunctioning pituitary adenomas
 

  • References

  • 1 Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. (eds.). Williams Textbook of Endocrinology. 12th edition Philadelphia, PA: Saunders Elsevier; 2011
  • 2 Gardner David G, Shoback D. Lange Textbook of Endocrinology. 9th edition 2011
    Google Scholar
  • 3 Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH, Wang HJ. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 2014; 232-239
    PubMedGoogle Scholar
  • 4 Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) 2010; 73: 502-527
    PubMedGoogle Scholar
  • 5 Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, Eigenthaler M, Lohmann T. Horm Differences in platelet activation by prolactin and leptin. Metab Res 2004; 36: 453-457
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T. Preclinical atherosclerosis in patients with prolactinoma. Endocrin Pract 2014; 20: 447-451
    PubMedGoogle Scholar
  • 7 Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 2013; 167: 1712-1718
    CrossrefPubMedGoogle Scholar
  • 8 Lombardi G, Di Somma C, Grasso LF, Savanelli MC, Colao A, Pivonello R. The cardiovascular system in growth hormone excess and growth hormone deficiency. Endocrinol Invest 2012; 35: 1021-1029
    PubMedGoogle Scholar
  • 9 Chanson P, Salenave S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology 2010; 92: 96-101
    CrossrefPubMedGoogle Scholar
  • 10 De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, De Martino MC, Lombardi G, Colao A. Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 2010; 92: 50-54
    CrossrefPubMedGoogle Scholar
  • 11 Jellinger PS, Smith DA, FACE . Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. American Association of clinical Endocrinologists guidelines for management of Dyslipidemia and prevention of Atherosclerosis. AACE Lipid and Atherosclerosis guidelines. Endocr Pract 2012; 18: 1
    CrossrefPubMedGoogle Scholar
  • 12 Kodiatte TA, Manikyam UK, Rao SB, Jagadish TM, Reddy M, Lingaiah HKM, Lakshmaiah V. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians 2012; 4: 5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-250
    CrossrefPubMedGoogle Scholar
  • 14 Nechita A, Delcea C, Enache V, Ploesteanu RL, Cazacu C, Andronescu AM, Stroi AM, Stamate CS. Metabolic syndrome and mean platelet volume variation in patients with chest pain and negative cardiac enzymes. J Med Life 2013; 6: 156-160
    PubMedGoogle Scholar
  • 15 Bath P, Algert C, Chapman N, Neal B. Group PC . Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-626
    CrossrefPubMedGoogle Scholar
  • 16 Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280: 187-193
    CrossrefPubMedGoogle Scholar
  • 17 Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815-830
    Google Scholar
  • 18 Doğan BA, Tuna MM, Arduç A, Nasiroğlu Nİ, Tütüncü Y, Işik S, Yilmaz M, Berker D, Güler S. Mean Platelet Volume and Lipid Profile in Non-obese Prolactinoma Patients Without Insulin Resistance. Turkiye Klinikleri. J Endocrinol 2014; 9: 33-38
    PubMedGoogle Scholar
  • 19 Gonzalez F, Sia CL, Bearson DM, Blair HE. Hyperandrogenism induces a proinflammatory TNFalpha response to glucose ingestion in a receptor-dependent fashion. J Clin Endocrinol Metab 2014; 99: E848-E854
    CrossrefPubMedGoogle Scholar
  • 20 Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 894-904
    CrossrefPubMedGoogle Scholar
  • 21 Wongwananuruk T, Rattanachaiyanont M, Leerasiri P, Indhavivadhana S, Techatraisa K. The Usefulness of HomeostaticMeasurement Assessment-Insulin Resistance (HOMA-IR) for Detection of Glucose Intolerance in ThaiWomen of Reproductive Age with Polycystic Ovary Syndrome. Int J Endocrinol 2012; Article ID 571035, 6 pages
    PubMedGoogle Scholar
  • 22 Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab 1996; 81: 2397-2400
    CrossrefPubMedGoogle Scholar
  • 23 Marshall S, Kledzik GS, Gelato M, Campbell GA, Meites J. Effects of estrogen and testosterone on specific prolactin binding in the kidneys and adrenal of rats. Steroids 1976; 27: 187-195
    CrossrefPubMedGoogle Scholar
  • 24 O’Connell Y, McKenna TJ, Cunningham SK. The effect of prolactin, human chorionic gonadotropin, insulin and insulin-like growth factor 1 on adrenal steroidogenesis in isolated guinea-pig adrenal cells. J Steroid Biochem Mol Biol 1994; 48: 235-240
    CrossrefPubMedGoogle Scholar
  • 25 Hagag P, Hertzianu I, Ben-Shlomo A, Weiss M. Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women. J Reprod Med 2001; 46: 678-684
    PubMedGoogle Scholar
  • 26 Belisle S, Menard J. Adrenal androgen production in hyperprolactinemic states. Fertil Steril 1980; 33: 396-400
    PubMedGoogle Scholar
  • 27 Green VL, Speirs V, Landolt AM, Foy PM, Atkin SL. 17β-Hydroxysteroid Dehydrogenase Type 1, 2, 3, and 4 Expression and Enzyme Activity in Human Anterior Pituitary Adenomas. J Clin Endocrinol Metab 1999; 84: 1340-1345
    PubMedGoogle Scholar
  • 28 Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88: 1389-1395
    CrossrefPubMedGoogle Scholar
  • 29 Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-488
    CrossrefPubMedGoogle Scholar